After months of anticipation, the new Community Pharmacy Contractual Framework has finally landed.
The settlement brings a funding uplift of around 10%, expands support for Pharmacy First and independent prescribing, and sets out the Government’s latest vision for the role community pharmacy should play within primary care.
Predictably, the reaction across the sector has been divided.
Some have welcomed the additional investment after years of financial pressure. Others argue it falls well short of what is needed to secure the future of the sector.
The truth probably sits somewhere in the middle.
There are undoubtedly positives within the settlement. Additional funding is welcome, particularly at a time when public finances remain under pressure and every part of the NHS is competing for investment.
The Government has also continued its shift towards more clinical services being delivered through pharmacy, recognising the increasingly important role the sector can play in improving access to care.
However, many contractors will look beyond the headline announcement and ask a simple question: does this go far enough?
The Government’s own economic review estimated that pharmacies spend between £4.3bn and £5.7bn delivering NHS pharmaceutical services, significantly above current funding levels.[1]
That context matters.
Against a challenge of that scale, a funding increase of around 10% starts to look less like a solution and more like an attempt to stabilise a sector that remains under considerable pressure.
Many contractors will argue that once inflationary pressures, rising staffing costs and increasing operational expenses are taken into account, the latest settlement offers limited improvement to their financial position.
That helps explain why the mood across much of the sector remains cautious rather than celebratory.
The latest contract may help pharmacies survive, but it does not come close to addressing the scale of the challenge highlighted by the Government’s own review.
Perhaps the clearest indication of that is the state of the network itself.
In March 2026, the number of community pharmacies in England fell below 10,000 for the first time.[2]
For a sector that is repeatedly described as the front door to the NHS, that should be a cause for concern.
Every closure means reduced access for patients, greater pressure on neighbouring pharmacies and one less healthcare destination available to local communities.
For years, ministers have spoken about moving more care into communities, reducing pressure on GPs and helping patients access treatment closer to home.
Community pharmacy is perfectly placed to support those ambitions.
Yet when opportunities arise to accelerate change, the response often feels cautious.
Take Pharmacy First.
The expansion of services is welcome and any move that gives patients greater access to care through their local pharmacy should be supported.
The inclusion of NHS-funded independent prescribing within Pharmacy First and contraception services is another positive step and signals where healthcare policy is heading.
But it is difficult not to question the pace of change.
Why are we still adding a relatively small number of additional pathways when pharmacy could safely support many more?
Why are we still talking about the future potential of independent prescribing when other parts of the UK are already further ahead?
The contrast with Scotland and Wales is becoming increasingly difficult to ignore.
Both nations have moved faster to position pharmacy as a genuine first point of contact for patients, investing in independent prescribing and expanding the range of conditions that can be managed within community pharmacy.
Meanwhile, England continues to move at a more measured pace. The direction of travel is similar, but the speed is not.
That matters because the NHS continues to face challenges that pharmacy is uniquely placed to help address.
Patients remain frustrated by difficulties securing appointments. Emergency departments continue to face significant demand. General practice remains under immense pressure.
At the same time, pharmacy remains one of the most accessible parts of the healthcare system, capable of supporting millions of patient interactions every year while helping direct demand away from other parts of the NHS.
The potential is obvious.
This is what makes the latest contract both encouraging and frustrating.
Encouraging because it demonstrates that ministers increasingly recognise the contribution community pharmacy can make.
Frustrating because the level of ambition still falls short of the scale of the opportunity.
Nobody expects every problem to be solved overnight.
The Government faces difficult financial decisions and every healthcare sector is making a case for additional investment.
But if community pharmacy is genuinely expected to play a greater role in the future of healthcare delivery, then reform needs to happen at a faster pace.
The latest settlement is a step forward.
The question is whether it is a big enough step.
For many contractors facing rising costs, increasing workload and ongoing financial uncertainty, the answer will be no.
The Government has acknowledged the potential of community pharmacy.
Now it needs to show the urgency and ambition required to fully realise it.
Sources
